https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(22)00337-8/fulltext
0
0
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2 - The Lancet
+ 142 more
1/18/23 at 11:30pm
Organization
The Lancet
Authors
Details
70 words
Summarize
Infectious Diseases general human use ABNCoV2 anti-SARS-CoV-2 The Lancet Immunisation SARS-CoV cVLP
Immunisation with ABNCoV2 was well tolerated, safe, and resulted in a functional immune response. The data support the need for additional clinical development of ABNCoV2 as a second-generation SARS-CoV-2 vaccine. The modular cVLP platform will accelerate vac…
Create an account or login to join the discussion